文献速递眼底病与葡萄膜炎

在随机XIRIUS 2/3期研究中评估cotoretigene toliparvovec治疗X连锁视网膜色素变性的视觉功能

Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.
PubMed 文献 · Ophthalmology · 2024-02-28

XIRIUS 2/3期研究纳入29例RPGR相关X连锁视网膜色素变性男性患者,随机接受低剂量或高剂量cotoretigene toliparvovec视网膜下注射或作为未治疗对照。主要终点微视野应答率未达统计学显著差异,但低剂量组在微视野平均敏感度和低亮度视力方面较对照组显著改善,且严重不良事件较少。

要点

  • 主要终点未达到:低剂量组37.5%、高剂量组25.0%与对照组22.2%的微视野应答率无显著差异。
  • 低剂量组微视野平均敏感度较对照组显著改善(P=0.0350),低亮度视力改善差异33.3%(80%CI 14.7%-55.2%,P=0.0498)。
  • 低剂量组发生3例眼部相关严重不良事件,高剂量组发生7例。

核心结论

  • 主要微视野终点未达到,但低剂量组较低亮度视力和平均微视野敏感度较对照组显著改善,且低剂量组严重不良事件少于高剂量组。

研究设计与样本

  • XIRIUS试验第2部分为2/3期、12个月、随机(1:1:1)剂量扩展研究,纳入29例RPGR相关X连锁视网膜色素变性男性患者(低剂量组n=10,高剂量组n=10,对照组n=9)。
  • 因COVID-19疫情影响,入组在达到初始目标前终止,试验把握度不足。

主要发现

  • 第12个月时,达到微视野应答标准(16个中心位点中≥5个位点改善≥7 dB)的参与者比例:低剂量组37.5%(P=0.3181)、高剂量组25.0%(P=0.5177)与对照组22.2%相比均无显著差异。
  • 第12个月时,低剂量组微视野平均敏感度较基线的平均变化较对照组显著改善(P=0.0350)。
  • 第12个月时,低剂量组低亮度视力较基线改善较对照组显著,差异为33.3%(80%置信区间14.7%-55.2%;P=0.0498)。
  • 低剂量组发生3例眼部相关严重不良事件,高剂量组发生7例。

关键数值与推荐

  • 微视野应答标准:16个中心位点中≥5个位点改善≥7 dB。
  • 低剂量为5×10^10载体基因组/眼,高剂量为2.5×10^11载体基因组/眼。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因COVID-19疫情影响,入组在达到初始目标前终止,试验把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cotoretigene toliparvovec (BIIB112/AAV8-RPGR) is an investigational vector-based gene therapy designed to provide a full-length, codon-optimized retinitis pigmentosa GTPase regulator (RPGR) protein to individuals with RPGR-associated X-linked retinitis pigmentosa (XLRP). We assessed efficacy and tolerability of cotoretigene toliparvovec subretinal gene therapy. DESIGN: Part 2 of the XIRIUS trial (ClinicalTrials.gov identifier, NCT03116113) was a phase 2/3, 12-month, randomized (1:1:1) dose-expansion study. PARTICIPANTS: Male patients ≥10 years of age with RPGR-associated XLRP were included. METHODS: Participants were randomized 1:1:1 to receive low-dose subretinal cotoretigene toliparvovec (5 × 1010 vector genomes/eye), high-dose cotoretigene toliparvovec (2.5 × 1011 vector genomes/eye) or to be an untreated control participant. MAIN OUTCOME MEASURES: The primary end point was the percentage of participants meeting microperimetry responder criteria (≥ 7-dB improvement at ≥ 5 of 16 central loci). Secondary end points included change from baseline in retinal sensitivity at the central 16 loci and the entire 68 loci at 12 months and change from baseline in low-luminance visual acuity (LLVA) at 12 months, as well as the proportion of eyes with a ≥ 15-Early Treatment Diabetic Retinopathy Study ETDRS letter LLVA and ≥ 10-ETDRS letter LLVA change from baseline at month 12. RESULTS: Because of the impact of the COVID-19 pandemic, enrollment ended before reaching the initial target, leaving the trial underpowered. Twenty-nine participants were included (low-dose group, n = 10; high-dose group, n = 10; control group, n = 9). At month 12, the percentage of participants meeting microperimetry responder criteria was not significantly different between either cotoretigene toliparvovec group (low dose, 37.5% [P = 0.3181]; high dose, 25.0% [P = 0.5177]) and the control group (22.2%). However, the mean change from baseline in microperimetry sensitivity improved significantly with the low-dose group versus the control group at month 12 (P = 0.0350). Significant improvement in LLVA occurred in the low-dose group versus the control group at month 12 (33.3% difference [80% confidence interval, 14.7%-55.2%]; P = 0.0498). Three ocular-related serious adverse events (SAEs) occurred in the low-dose group versus 7 SAEs in the high-dose group. CONCLUSIONS: The primary microperimetry end point was not met. Significant improvements in LLVA and mean microperimetry were observed compared with controls and fewer SAEs occured with low-dose compared with high dose cotoretigene toliparvovec. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Lam BL, Pennesi ME, Kay CN, et al. Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study. Ophthalmology. 2024. PMID: 38423215. doi:10.1016/j.ophtha.2024.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。